Compare American Financial Group Inc (AFG) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Financial Group Inc vs Merck & Co., Inc. — how do they compare? American Financial Group Inc trades at $144.42 (market cap $11.97B), while Merck & Co., Inc. trades at $132.51 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 26.9× American Financial Group Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| AFG | MRK | |
|---|---|---|
Market Cap | $11.97B | $321.77B |
Sector | Financials | Health |
52-Week High | $148.71 | $131.84 |
52-Week Low | $124.18 | $77.60 |
Enterprise Value | $12.35B | $368.53B |
Dividend Yield | 2.44% | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AFG trades at $142.77, down 0.76% on the day, with a bullish technical signal supported by moving averages and a neutral RSI near 59. The stock shows consistent profitability with a net income margin of 11.66% and ROE of 20.41%, though revenue dipped slightly in 2025. Recent Q2 2026 earnings beat estimates, driven by strong P&C underwriting and investment income, as reported by Business Wire on August 4, 2026.
The outlook remains positive with a consensus price target of $160.67, implying 12.5% upside. Risks include potential earnings volatility and competitive pressures in the insurance sector. Analyst sentiment is mixed with 41% buy ratings, but no sell recommendations, supporting a cautiously optimistic view for long-term investors.
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Financial Group Inc
American Financial Group Inc is a holding company that is engaged primarily in property and casualty insurance services. The company has a focus on specialized commercial products for businesses. American also has annuity operations that are focused on sales of traditional fixed and fixed-indexed annuities in the education, bank, and individual markets. American's insurance operations are conducted through the Great American Insurance Group. The group writes business in all 50 of the United States, primarily through independent agents and brokers.
Read more on AFG →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
